-- Isis Earns $27 Million Milestone Payment
-- CHERISH Trial to Enroll 120 Children With SMA at Clinical Centers Globally
CARLSBAD, Calif., Nov. 25, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the initiation of a pivotal Phase 3 study evaluating ISIS-SMNRx in approximately 120 non-ambulatory children with spinal muscular atrophy (SMA). SMA is a severe and rare genetic neuromuscular disease characterized by muscle atrophy and weakness. The Phase 3 study,...
CARLSBAD, Calif., Nov. 20, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that data from two drugs in its anti-cancer franchise will be presented by researchers at AstraZeneca in three presentations at the 26th European Organization for Research and Treatment of Cancer (EORTC) – the National Cancer Institute (NCI) – and the American Association for Cancer Research (AACR) symposium. Results from a Phase 1/2 clinical study presented today provided preliminary evide...
CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)--Nov. 18,
Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc. (NASDAQ: ISIS), today
announced that new two-year data from a phase 3 long-term extension study of
KYNAMRO® (mipomersen sodium) injection was presented at a scientific
session at the annual American Heart Association meeting in Chicago, IL. In the study,
a retrospective analysis showed that patients treated with KYNAMRO for a mean of
two years had a sign...
- Webcast scheduled on Monday, December 8 at 9:00 a.m. Eastern Time
CARLSBAD, Calif., Nov. 18, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it will host a live webcast on Monday, December 8, 2014 at 9:00 a.m. Eastern Time to discuss the ISIS-FXIRx data presented at the 56th American Society of Hematology Annual Meeting and Exposition.
Interested parties may listen to the call by dialing 877-443-5662 or access the webcast at www.isispharm.com. A w...
If you are interested in Isis Pharmaceuticals’ investment details, please visit our Investor FAQ page.
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Online Investor Kit
Quickly download files right from our Investor Relations Web site.